Amgen Inc. stock (US0311621009): focus on Repatha growth as first-quarter 2026 results mix

Amgen Inc. reported mixed first?quarter 2026 results while highlighting strong growth for cholesterol drug Repatha and progress on its Horizon Therapeutics integration. What the latest numbers mean for the biotech heavyweight’s long?term story.

Amgen Inc. is back in the spotlight after publishing financial results for the first quarter of 2026 that showed solid top?line growth but some pressure on profitability, while management again emphasized the potential of newer products such as Repatha and the ongoing integration of Horizon Therapeutics. According to the company’s quarterly update released in late April 2026, revenue increased year over year, driven by key cardiovascular and bone health therapies, although higher operating costs and R&D investments weighed on margins, as reported in the filing cited by Reuters as of 04/30/2026.

In the same announcement, Amgen’s management highlighted that sales of its PCSK9 inhibitor Repatha continued their double?digit expansion, offsetting declines in certain legacy brands and the impact of biosimilar competition. The company also reiterated its focus on integrating the Horizon portfolio, including rare disease treatment Tepezza, and reaffirmed its full?year 2026 revenue guidance range, according to the earnings communication referenced by Amgen Investor Relations as of 04/30/2026.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biotechnology, biopharmaceuticals
• Headquarters/country: Thousand Oaks, California, United States
• Core markets: United States, Europe, selected international markets
• Key revenue drivers: Innovative biologic therapies for cardiovascular disease, oncology, bone health, inflammation and rare diseases
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: US dollar (USD)

Amgen Inc.: core business model

Amgen is one of the largest independent biotechnology groups worldwide, with a business model that spans the full value chain from early?stage research through clinical development, manufacturing and global commercialization of biologic medicines. The company historically built its franchise in areas such as anemia and bone health but has over time diversified into oncology, cardiovascular disease, inflammatory disorders and, more recently, rare conditions. This focus on serious, often chronic diseases underpins a portfolio that tends to generate recurring revenue streams over long treatment durations.

Biologic drugs are at the heart of Amgen’s strategy. These complex protein?based therapies are produced using living cells and often target specific pathways implicated in disease, which can support premium pricing and differentiated clinical outcomes compared to traditional small?molecule pharmaceuticals. However, biologics also come with high development and manufacturing costs, and increasing competition from biosimilars once patents expire. Amgen navigates this landscape both as an originator of branded biologics and, in some cases, as a producer of biosimilar products that compete with other companies’ brands, according to product descriptions in recent company materials summarized by Amgen corporate information as of 03/2026.

The group’s business is organized around therapeutic franchises that bundle R&D efforts, marketing, medical affairs and market access strategies. Blockbuster brands such as Enbrel for inflammatory diseases, Prolia and Xgeva for bone health, and Repatha for cardiovascular risk reduction form the backbone of revenue, complemented by oncology agents and newer launches. The company also invests heavily in platform technologies like human genetics, antibody engineering and targeted therapies to identify and validate novel drug targets, aiming to build a sustainable pipeline that can replenish revenue as older therapies lose exclusivity. This model requires substantial ongoing R&D spending, but successful launches can potentially support high margins and cash flows over time.

Main revenue and product drivers for Amgen Inc.

Recent quarters have illustrated how Amgen’s revenue mix is gradually shifting from older biologics to newer growth drivers. In its first?quarter 2026 report, management pointed to continued softness in some mature products facing competitive and pricing pressures, while highlighting the strength of Repatha, Prolia and key oncology agents as the main contributors to top?line expansion, as summarized in the earnings release noted by Amgen Investor Relations as of 04/30/2026. Repatha, which lowers LDL cholesterol by inhibiting PCSK9, has benefited from broader reimbursement in major markets and growing physician familiarity in both primary and secondary prevention of cardiovascular events.

Bone health products such as Prolia and Xgeva remain important pillars of the portfolio, particularly for postmenopausal osteoporosis and oncology?related bone complications. Demand in these segments tends to be relatively resilient because patients often require long?term treatment and the underlying conditions are closely monitored by specialists. However, payers in the United States and Europe continue to scrutinize pricing, which can influence net revenue growth even when volumes rise. In oncology and hematology, Amgen markets therapies for multiple myeloma, leukemia and other malignancies, though competition from other biotechs and large pharmaceutical companies is intense, according to sector coverage compiled by Bloomberg as of 04/2026.

The acquisition of Horizon Therapeutics, completed in 2024, introduced a portfolio of rare disease and autoimmune products that are progressively being integrated into Amgen’s commercial infrastructure. Key assets such as Tepezza for thyroid eye disease and Krystexxa for uncontrolled gout have relatively concentrated patient populations but command high per?patient revenues, which can support overall growth while adding therapeutic diversification. In the first quarter of 2026, management indicated that Horizon?derived products continued to contribute meaningfully to overall sales, as described in the company’s update referenced by Amgen Investor Relations as of 04/30/2026.

Beyond branded medicines, Amgen also participates in the biosimilar market, supplying versions of established biologics such as bevacizumab, trastuzumab and infliximab in several regions. While unit prices for biosimilars are typically lower than for originator products, the market opportunity is substantial due to high patient volumes and payers’ interest in cost savings. This dual positioning—as both an originator and a biosimilar producer—gives Amgen diversified exposure across different price points and therapeutic categories, but it also requires careful portfolio management to avoid internal cannibalization where its own originator drugs compete with its biosimilars.

Conclusion

Amgen Inc. enters the remainder of 2026 with a portfolio that blends established cash?generating biologics, expanding franchises such as Repatha and Prolia, and newer rare disease assets from the Horizon Therapeutics acquisition. The latest quarterly report shows that revenue growth remains positive but that margins are sensitive to higher R&D and integration costs, underscoring the need for continued pipeline execution and disciplined expense management. For US and international investors following large?cap biotechnology, Amgen represents a mature player navigating patent cycles, payer pressures and competitive dynamics while seeking to unlock additional value from its pipeline and acquired therapies, without the article expressing any recommendation on how to act on the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.